Polymyxin B and colistimethate are comparable as to efficacy and renal toxicity.
We compared 41 patients who received colistimethate with 41 who received polymyxin B for the treatment of serious infections caused by carbapenem-resistant Acinetobacter spp. and found both polymyxins have similar efficacy and toxicity.
Oliveira
Maura S
MS
Department of Infection Control of Hospital das Clínicas, Rua Dr. Ovídio Pires de Campos, São Paulo-SP 05403-010, Brazil.
Prado
Gladys V B
GV
Costa
Silvia F
SF
Grinbaum
Renato S
RS
Levin
Anna S
AS
D000151:Acinetobacter Infections / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D003091:Colistin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D011112:Polymyxin B / Q000009:adverse effects* / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
D000900:Anti-Bacterial Agents; C004691:colistinmethanesulfonic acid; D011112:Polymyxin B; D003091:Colistin